| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 439 | 2021 |
| Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by … G Masi, F Loupakis, L Pollina, E Vasile, S Cupini, S Ricci, IM Brunetti, ... Annals of surgery 249 (3), 420-425, 2009 | 322 | 2009 |
| Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients C Raimondi, A Gradilone, G Naso, B Vincenzi, A Petracca, C Nicolazzo, ... Breast cancer research and treatment 130, 449-455, 2011 | 317 | 2011 |
| Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization A Gradilone, G Naso, C Raimondi, E Cortesi, O Gandini, B Vincenzi, ... Annals of Oncology 22 (1), 86-92, 2011 | 170 | 2011 |
| Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal A Gradilone, C Raimondi, C Nicolazzo, A Petracca, O Gandini, B Vincenzi, ... Journal of cellular and molecular medicine 15 (5), 1066-1070, 2011 | 123 | 2011 |
| Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology R Gradini, M Realacci, A Ginepri, G Naso, C Santangelo, O Cela, P Sale, ... The Journal of pathology 189 (2), 224-229, 1999 | 119 | 1999 |
| Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials R Iacovelli, D Alesini, A Palazzo, P Trenta, M Santoni, L De Marchis, ... Cancer treatment reviews 40 (2), 271-275, 2014 | 110 | 2014 |
| Molecular markers in circulating tumour cells from metastatic colorectal cancer patients P Gazzaniga, A Gradilone, A Petracca, C Nicolazzo, C Raimondi, ... Journal of cellular and molecular medicine 14 (8), 2073-2077, 2010 | 92 | 2010 |
| Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials R Iacovelli, A Palazzo, S Mezi, F Morano, G Naso, E Cortesi Acta Oncologica 51 (7), 873-879, 2012 | 91 | 2012 |
| Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors P Gazzaniga, G Naso, A Gradilone, E Cortesi, O Gandini, W Gianni, ... International Journal of Cancer 126 (10), 2437-2447, 2010 | 70 | 2010 |
| Prognostic significance of survivin‐expressing circulating tumour cells in T1G3 bladder cancer A Gradilone, A Petracca, C Nicolazzo, W Gianni, E Cortesi, G Naso, ... BJU international 106 (5), 710-715, 2010 | 69 | 2010 |
| PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy? B Cerbelli, A Pernazza, A Botticelli, L Fortunato, M Monti, P Sciattella, ... BioMed research international 2017, 2017 | 63 | 2017 |
| Clinical utility of circulating tumor cell counting through CellSearch®: the dilemma of a concept suspended in Limbo C Raimondi, A Gradilone, G Naso, E Cortesi, P Gazzaniga OncoTargets and therapy, 619-625, 2014 | 59 | 2014 |
| High frequency of human papillomavirus detection in urinary bladder cancer AM Aglianò, A Gradilone, P Gazzaniga, M Napolitano, R Vercillo, ... Urologia internationalis 53 (3), 125-129, 1994 | 59 | 1994 |
| Pancreatic cancer: from molecular signature to target therapy R Longo, F Cacciamani, G Naso, G Gasparini Critical reviews in oncology/hematology 68 (3), 197-211, 2008 | 51 | 2008 |
| Alteration of growth and differentiation factors response by Kirsten and Harvey sarcoma viruses in the IL-3-dependent murine hematopoietic cell line 32D C13 (G). F Mavilio, BL Kreider, M Valtieri, G Naso, N Shirsat, D Venturelli, ... Oncogene 4 (3), 301-308, 1989 | 42 | 1989 |
| Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? P Papaldo, G Ferretti, S Di Cosimo, D Giannarelli, P Marolla, M Lopez, ... Journal of clinical oncology 24 (19), 3048-3055, 2006 | 40 | 2006 |
| T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study B Conte, A Fabi, F Poggio, E Blondeaux, C Dellepiane, A D’Alonzo, ... Clinical Breast Cancer 20 (2), e181-e187, 2020 | 37 | 2020 |
| Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis KA Gelmon, PA Fasching, FJ Couch, J Balmaña, S Delaloge, ... European Journal of Cancer 152, 68-77, 2021 | 26 | 2021 |
| Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature M Framarino-dei-Malatesta, A Chiarito, F Bianciardi, M Fiorelli, A Ligato, ... BMC cancer 19, 1-10, 2019 | 24 | 2019 |
